ArticleDiagnostic pathology2026
PRAME immunohistochemistry demonstrates high diagnostic accuracy for distinguishing melanoma from nevi but no observed association with pT stage in cutaneous melanoma: a Vietnamese clinicopathological study.
Article in Diagnostic pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPRAME immunohistochemistry is a useful adjunct in distinguishing melanoma from benign melanocytic lesions, but its clinicopathologic associations remain incompletely understood, particularly in underrepresented populations.
methodsThis retrospective study included 90 primary melanomas and 90 melanocytic nevi from a Vietnamese cohort. PRAME expression (clone EPR20330) was assessed using a semi-quantitative scoring system: 0 (0%), 1+ (1-25%), 2+ (26-50%), 3+ (51-75%), and 4+ (> 75% of tumor cells with nuclear positivity), with 4 + defined as high expression. Diagnostic performance was evaluated using receiver operating characteristic (ROC) analysis, and associations with clinicopathologic variables were analyzed using logistic regression.
resultsThe mean age of melanoma patients was 56.4 ± 15.9 years, with a median tumor size of 30 mm. Nodular melanoma was the most common subtype (60%), and mucosal melanoma accounted for 15.6%. Adverse features were common, including Breslow thickness > 1 mm (87.8%), mitotic rate > 1/mm² (85.6%), and ulceration (36%). High PRAME expression was observed in 73.3% of melanomas, whereas 97.8% of nevi were negative and none showed PRAME ≥ 2+. PRAME demonstrated excellent diagnostic performance (AUC 0.936), with sensitivity, specificity, and accuracy of 87.8%, 97.8%, and 92.8% at a cutoff of ≥ 1+. Tumor size > 12 mm was independently associated with high PRAME expression in the overall cohort but not in cutaneous melanoma. No statistically significant associations were observed between PRAME expression and tumor stage in cutaneous melanoma.
conclusionsIn this predominantly advanced-stage Vietnamese cohort, PRAME immunohistochemistry showed high sensitivity and specificity in distinguishing melanoma from nevi; its performance in early or thin melanomas and its broader clinicopathologic significance remain to be clarified in future studies.
Indexed as
Identifiers
42458521What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.